Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 10,000 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 10,000 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $28.42, for a total transaction of $284,200.00. Following the sale, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at approximately $10,292,359.84. This trade represents a 2.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

• On Monday, April 20th, Claire Mazumdar sold 15,000 shares of Bicara Therapeutics stock. The shares were sold at an average price of $23.61, for a total transaction of $354,150.00.

Bicara Therapeutics Trading Down 0.2%

BCAX traded down $0.05 during trading on Tuesday, hitting $28.10. 331,455 shares of the company’s stock were exchanged, compared to its average volume of 605,796. Bicara Therapeutics Inc. has a 1 year low of $9.57 and a 1 year high of $30.99. The stock has a 50 day moving average price of $23.56 and a 200 day moving average price of $20.19. The firm has a market cap of $1.85 billion, a P/E ratio of -10.11 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Analysts forecast that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BCAX has been the topic of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. Wells Fargo & Company upped their target price on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. Wedbush reiterated an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a report on Tuesday, March 31st. Finally, HC Wainwright boosted their price target on Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $30.27.

Hedge Funds Weigh In On Bicara Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC grew its position in shares of Bicara Therapeutics by 26.2% during the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock worth $66,350,000 after buying an additional 692,933 shares in the last quarter. Rock Springs Capital Management LP raised its holdings in Bicara Therapeutics by 14.0% in the first quarter. Rock Springs Capital Management LP now owns 489,095 shares of the company’s stock valued at $9,728,000 after acquiring an additional 60,000 shares in the last quarter. Quantinno Capital Management LP raised its holdings in Bicara Therapeutics by 16.1% in the first quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after acquiring an additional 2,447 shares in the last quarter. Orbimed Advisors LLC boosted its stake in Bicara Therapeutics by 219.1% during the 1st quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock valued at $13,273,000 after acquiring an additional 458,200 shares during the last quarter. Finally, Siren L.L.C. boosted its stake in Bicara Therapeutics by 11.2% during the 1st quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock valued at $115,421,000 after acquiring an additional 586,001 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.